Table 2 Pathological characteristics of patients with IgAN and IgAVN included in the present study and control subjects

Median time from presentation to biopsy (months) (range)

20 (6–40)

5 (0.5-9)

2 (0.5–12) #

4 (0.5–15) #

Median % of global sclerotic glomeruli (range)

9.7 (0-44.4)

35.3 (2.9–47.1)

7.8 (0–16.0)

7.5 (2.5–23.8)

Oxford classification, n

 M score

1 M0, 5 M1

2 M0, 4 M1

 E score

3 E0, 3 E1

5 E0, 1 E1

 S score

3 S0, 3 S1

3 S0, 3 S1

 T score

4 T0, 2 T1

3 T0, 1 T1, 2 T2

 C score

2 C0, 4 C1

1 C0, 4 C1, 1 C2

ISKDC classification grade, n

1 II, 2 IIIa, 3 IIIb

1 IIIa, 5 IIIb

 % of glomeruli with crescent formation

0, 2.5, 2.7, 4.8, 6.7, 8.0

21.2, 25.7, 27.9, 31,3, 33.3, 44.8

Glomerular deposition (IF intensities), n

 IgA

5 (2+), 1 (3+)

2 (+), 4 (2+)

2 (+), 4 (2+)

1 (+), 5 (2+)

 IgA1

6 (+)

5 (+), 1 (2+)

5 (+), 1 (2+)

1 (±), 4 (+), 1 (2+)

 IgA2

6 (‒)

6 (‒)

6 (‒)

5 (‒), 1 (±)

 IgG

3 (‒), 1 (±), 2 (+)

3 (‒), 1 (±), 2 (+)

3 (‒), 1 (±), 2 (+)

4 (‒), 1 (±), 1 (+)

 IgM

1 (‒), 3 (±), 2 (+)

2 (‒), 2 (±), 2 (+)

4 (‒), 1 (±), 1 (+)

4 (‒), 1 (±), 1 (+)

 κ

4 (+), 2 (2+)

2 (±), 2 (+), 2 (2+)

2 (±), 2 (+), 2 (2+)

2 (‒), 3 (+), 1 (2+)

 λ

4 (+), 2 (2+)

1 (±), 2 (+), 3 (2+)

6 (+)

6 (+)

 C3

4 (+), 2 (2+)

1 (‒), 1 (±), 1 (+), 3 (2+)

1 (‒), 3 (+), 2 (2+)

1 (‒), 1 (±), 2 (+), 2 (2+)

 C1q

5 (‒), 1 (±)

6 (‒)

6 (‒)

6 (‒)